Baby Safety / Compounds / Afoxolaner (NexGard)

Is Afoxolaner (NexGard) safe for babies and kids?

Moderate risk for kids

Infants have immature drug-metabolizing enzymes (CYP450 ontogeny), reduced renal clearance, and different volume of distribution. Accidental exposure or breast milk transfer of Afoxolaner (NexGard) poses heightened risk.

What is afoxolaner (nexgard)?

The IUPAC name is 4-[5-[3-chloro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-1,2-oxazol-3-yl]-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]naphthalene-1-carboxamide.

Also known as: 4-[5-[3-chloro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-1,2-oxazol-3-yl]-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]naphthalene-1-carboxamide, Afoxolaner, NEXGARD, 02L07H6D0U.

IUPAC name
4-[5-[3-chloro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-1,2-oxazol-3-yl]-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]naphthalene-1-carboxamide
CAS number
1093861-60-9
Molecular formula
C26H17ClF9N3O3
Molecular weight
625.9 g/mol
SMILES
C1C(=NOC1(C2=CC(=CC(=C2)Cl)C(F)(F)F)C(F)(F)F)C3=CC=C(C4=CC=CC=C43)C(=O)NCC(=O)NCC(F)(F)F
PubChem CID
25154249

Risk for babies

Moderate risk

Infants have immature drug-metabolizing enzymes (CYP450 ontogeny), reduced renal clearance, and different volume of distribution. Accidental exposure or breast milk transfer of Afoxolaner (NexGard) poses heightened risk.

Neonates and infants up to 12 months have incomplete blood-brain barrier development, immature Phase I/II metabolic enzymes (particularly CYP3A4, UGT1A1), and higher gastrointestinal permeability. Equivalent doses produce higher internal concentrations and longer residence times.

What to do: Minimize infant exposure through source control. For breastfeeding mothers: reduce maternal exposure. For formula-fed infants: use certified low-migration bottles and verified water sources. Consult pediatrician regarding any concerns.

Risk for pregnant and nursing people

Elevated risk

Afoxolaner (NexGard) poses pregnancy risk through potential teratogenicity, altered pharmacokinetics (increased blood volume, changed CYP activity), and placental transfer. FDA pregnancy category should be evaluated.

Suspected reproductive toxicant (GHS H361) or suspected endocrine disruptor. Precautionary approach warranted. Animal studies or limited human data suggest developmental toxicity potential.

What to do: Minimize exposure during pregnancy and lactation. Consult healthcare provider regarding specific risks. Consider alternative products with lower hazard profiles.

Regulatory consensus

1 regulatory bodyhas classified Afoxolaner (NexGard).

AgencyYearClassificationNotes
IARC2022Not evaluated by IARC — afoxolaner (NexGard; Boehringer Ingelheim) is an FDA/CVM-approved isoxazoline ectoparasiticide for dogs; monthly flavored chewable tablet for flea and tick prevention and treatment; FDA 2018 class-wide neurological adverse event warning (isoxazoline class); no carcinogenicity classification

Regulators apply different standards of evidence — animal-data weighting, exposure-pattern assumptions, epidemiological power thresholds — which is why two scientific bodies can review the same data and reach different conclusions. The disagreement is the data.

Where kids encounter afoxolaner (nexgard)

  • Industrial Facilities — Manufacturing plants, Chemical storage areas, Waste treatment sites
  • Occupational Environments — Factories, Warehouses, Transportation vehicles

Safer alternatives

Lower-risk approaches that achieve a similar outcome to Afoxolaner (NexGard):

  • Alternative drug class; Non-pharmacological therapy; Lowest effective dose
    Trade-offs: Direct chemical substitution requires verification that the replacement does not introduce new hazards (regrettable substitution). Conduct full hazard assessment of proposed alternative before adoption.
    Relative cost: 1.2-2×

Frequently asked questions

Is afoxolaner (nexgard) safe for kids?

Infants have immature drug-metabolizing enzymes (CYP450 ontogeny), reduced renal clearance, and different volume of distribution. Accidental exposure or breast milk transfer of Afoxolaner (NexGard) poses heightened risk.

What products contain afoxolaner (nexgard)?

Afoxolaner (NexGard) appears in: Manufacturing plants (Industrial facilities); Chemical storage areas (Industrial facilities); Factories (Occupational environments); Warehouses (Occupational environments).

What should I do if my child is exposed to afoxolaner (nexgard)?

Minimize infant exposure through source control. For breastfeeding mothers: reduce maternal exposure. For formula-fed infants: use certified low-migration bottles and verified water sources. Consult pediatrician regarding any concerns.

See Afoxolaner (NexGard) in the baby app

Look up products containing afoxolaner (nexgard), compare to alternatives, and explore the full data record.

Open in baby View raw API data

Sources (1)
  1. Afoxolaner NexGard Boehringer Ingelheim FDA CVM 2013; Isoxazoline GABA Chloride Channel Dog Only Monthly; FDA 2018 Class Neurological Warning Tremors Ataxia Seizures; Half-Life 14-15 Days CYP3A4 Hepatic; Beef-Flavored Chewable Flea Tick Ixodes Dermacentor Amblyomma; Post-Marketing Pharmacovigilance; EMA EU Approved; IARC Not Evaluated; Aquatic EMA VMP Assessment; NexGard Spectra Milbemycin Combination (2022) — regulatory

Reference data, not professional advice. Aggregates publicly available regulatory and scientific data; not a substitute for veterinary, medical, legal, or regulatory advice. Why we built ALETHEIA →